University of Michigan Comprehensive Cancer Center Support Grant

描述(由申请人提供)：密歇根大学综合癌症中心(UMCCC)自1988年首次获得NCI奖以来，请求第六次续签其核心补助金。癌症中心的创始主任Max Wicha博士继续担任主任，并得到一个强大的、国家认可的高级领导团队的支持。该中心提供了一个组织框架，通过在癌症研究中开发资金充足的基础、临床和预防计划以及开发共享的核心资源来促进跨学科的癌症研究。癌症中心的13个研究项目包括癌症遗传学、癌细胞生物学、放射科学、分子成像、实验治疗学和肿瘤免疫学宿主反应的6个基础研究项目；5个临床研究项目：血液恶性肿瘤/BMT、乳腺癌、前列腺癌、G1和头颈部癌症；以及两个预防项目：生物医学和社会行为。共请求支助18个共享核心设施，包括13个现有核心设施。临床试验、生物统计学、组织和分子病理学、肿瘤成像、形态学、流式细胞术、实验照射、转基因小鼠、载体、免疫监测、基因组学、信息学、健康通信和五个新核心：患者和人口科学、高通量筛选、药代动力学、结构生物学和异种移植。还需要资金用于发展、高级领导、规划和评估以及支持中心目标的管理。 UMCCC的337名成员在这段时间内贡献了许多具有重大影响的发现。癌症中心的使命是“通过创新和协作征服癌症”，这一资助期间出版的内部(15.6%)和跨部门(35.4%)计划出版物的高程度进一步证明了这一点。UMCCC目前在所有矩阵癌症中心中排名第一，这突显了该中心的成功。医学中心继续在太空、财政支持和将癌症列为其临床和研究投资的最优先事项之一方面向癌症中心作出实质性承诺。收购辉瑞的前园区，现在称为北校园研究综合体，代表着在下一个赠款期间发现癌症的一个无与伦比的机会。

DESCRIPTION (provided by applicant): The University of Michigan Comprehensive Cancer Center (UMCCC) requests the sixth renewal of its core grant since the initial NCI award in 1988. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director, supported by a strong, nationally recognized senior leadership team. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of well-funded basic, clinical and prevention programs in cancer research and the development of shared core resources. The Cancer Center's 13 research programs include six basic research programs in Cancer Genetics, Cancer Cell Biology, Radiation Sciences, Molecular Imaging, Experimental Therapeutics and Tumor Immunology Host Response; five clinical research programs: Hematologic Malignancies/BMT, Breast, Prostate, Gl and Head and Neck cancers; and two prevention programs Biomedical and Sociobehavioral. Support is requested for a total of 18 shared core facilities, including 13 existing cores. Clinical Trials, Biostatistis, Tissue and Molecular Pathology, Tumor Imaging, Morphology, Flow Cytometry, Experimental Irradiation, Transgenic Mouse, Vector, Immune Monitoring, Genomics, Informatics, Health Communications and five new cores: Patient and Population Sciences, High Throughput Screening, Pharmacokinetics, Structural Biology and Xenograft. Funds are also requested for development, senior leadership, planning and evaluation and administration to support center goals. The UMCCC's 337 members have contributed many high impact discoveries over this grant period. The Cancer Center's mission of "the conquest of cancer through innovation and collaboration" is further evidenced by the high degree of intra- (15.6%) and inter- (35.4%) programmatic publications published in this grant period. The UMCCC's success is underscored by its current ranking as #1 in NCI funding among all matrix cancer centers. The Medical Center has continued to make substantial commitments to the Cancer Center in space, financial support and designation of cancers as among its highest priorities for both clinical and research investment. The acquisition of the former Pfizer campus, now called North Campus Research Complex, represents an unparalleled opportunity for cancer discovery over the next grant period.